Currently Funded Projects:


Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness Trial
This trial will compare low vs. standard-dose aspirin therapy on cardiovascular disease events in adults with heart disease.
Funding Source: Patient Centered Outcomes Research Institute
PI:
Matthew Roe, MD, Duke University; Site PI: Jeffrey VanWormer, PhD


Center for Research to Optimize Precision Lung Cancer Screening in Diverse Populations (PROSPR II)
The long-term goal of this multi-site center grant is to identify critical gaps in the lung cancer screening process and to design innovative, multi-level interventions to reduce lung cancer mortality, particularly among underserved populations.
Funding Source: Kaiser Foundation Research Institute/NCI
PI:
Deb Ritzwoller, Kaiser Permanente Colorado; Site PI: Robert Greenlee, PhD, MPH


Central Data Collection Center (CDCC) - Continued Follow-up of PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) Participants
This project involves ongoing followup of a randomized cancer screening trial of more than 20 years duration involving 74,000 females and 74,000 males aged 55-74 at entry at 10 sites around the country. Individuals in the control group received usual medical care. Individuals in the group randomized to screening received screening examinations for lung, and colo-rectal cancers and, depending on sex, either prostate or ovarian cancer. The screening trial was designed to determine whether: 1) screening with flexible sigmoidoscopy can reduce mortality from colo-rectal cancer; 2) screening with chest x-ray can reduce mortality from lung cancer; 3). screening men with digital rectal examination plus serum prostate-specific antigen can reduce mortality from prostate cancer; and, 4). screening women with CA 125 and transvaginal ultrasound can reduce mortality from ovarian cancer. Secondary objectives included: 1) to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive values. 2) To assess incidence, stage, and survival experience of cancer cases. 3) To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.  To view publications and results, click here.
Funding Source: Westat/NCI
PI: Robert Greenlee, PhD, MPH


National Cancer Institute (NCI) Cohort Study - Planning Phase
Cancer is the second leading cause of death in the United States and has substantial negative impact on human health and well-being. Yet much remains to be learned regarding the factors that influence a person's risk of developing or dying from cancer. Marshfield Clinic Research Institute (MCRI) and two other Midwestern health care systems, HealthPartners (Minneapolis) and Henry Ford Health System (Detroit), have been funded by the U.S. National Cancer Institute to plan a large national cohort study of cancer occurrence and outcomes in adults. At these sites and others across the U.S., participants will be followed over a decade or more to provide new information on cancer causes and strategies to improve survival and quality of life. The MCRI research team will develop and test study recruitment and follow-up procedures during the planning phase.
Funding Source: National Cancer Institute (NCI)
Consortium PI: Ben Rybicki, PhD, Henry Ford Health System; Site PI: Robert Greenlee, PhD, MPH


Molecular Profiling of Ductal Carcinoma in Situ (DCIS) and Risk of Subsequent Invasive Breast
The goal of this multi-site study is to identify tumor markers for risk of progression from having DCIS to developing subsequent invasive breast cancer. This work follows extensive collaborative pilot work with Einstein College of Medicine and several other sites in the Cancer Research Network. To view publication: click here
Funding Source: Einstein College of Medicine/NCI
PI: Thomas Rohan, Einstein College of Medicine; Site PI/Co-Investigator: Robert Greenlee, PhD, MPH


Preparing to Prioritize CVD (Cardiovascular Disease) Strategies in Rheumatoid Arthritis and Lupus: P2P-CVD
In the general population, attributable risks have been critical to identify U.S. and global preventive care priorities. However, attributable risks in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are unknown. Filling the critical knowledge gap of attributable risks for CVD and death in RA and SLE will inform selecting the most important targets for a clinical intervention study to improve risk factor control and event-free survival.
Funding Source: University of Wisconsin/Rheumatology Research Foundation
PI: Christie Bartels, University of Wisconsin; Co-Investigator: Robert Greenlee, PhD, MPH


Surveillance of Pediatric Obesity Patterns in Wisconsin
This study will characterize circannual trends in body weight among children and adolescents using electronic health records.
Funding Source: University of Wisconsin Institute for Clinical and Translational Research
PI: Jeffrey VanWormer, PhD


Periodontal Disease and Risk of Heart Failure: The PERIDISE Case-Control Study in Wisconsin Adults
This study will examine the association between periodontal disease and incident heart failure in Wisconsin adults.
Funding Source: Celine Seubert Distinguished Physician/Scientist Endowment in Cardiology Research
PI: Jeffrey VanWormer, PhD


Recently Completed Projects:


CVRN-Risks with ICD Placement and Outcomes in Kidney Disease (CVRN-RISK) Study

The aims of this bridge award were: 1) to understand the extent to which patients with heart failure with reduced left ventricular ejection fraction and concomitant reduced kidney function receive guideline-based primary prevention ICDs (implantable cardioverter defibrillators) compared with patients with preserved kidney function; 2) to clarify the effect of kidney function level on complications, hospitalization and death among heart failure patients who do and do not receive an ICD. To view publication and results: click here 
Funding Source:
University of Washington/NHLBI
PI:
Nisha Bansal, University of Washington; Site PI: Robert Greenlee, PhD, MPH


Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
This project developed a cohort of adults with Venous Thromboembolism (VTE) that was used to answer numerous research questions about optimal VTE management within real-world practice settings. Treatment patterns and risk factors were used to predict recurrent VTE and major hemorrhagic complications.
Funding Source: National Heart, Lung, and Blood Institute
PI: Margaret Fang, MD, UCSF School of Medicine; Site PI: Jeffrey VanWormer, PhD


ESA Outcomes Among Anemic CKD Patients
This retrospective cohort study examined outcomes associated with differential use of Erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease who are anemic.
Funding Source: Agency for Healthcare Research & Quality
PI: Dennis Cotter, Medical Technology and Practice Patterns Institute; Site PI/Co-Investigator: Jeffrey VanWormer, PhD